RxDoctor Payments Data

Joseph Jacob, MD

Urology · Syracuse, NYNPI 1235440090

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,180 of the $39,264 with a category attached, or 76.9%. 9 manufacturers reported payments, led by Urogen Pharma, Inc. at 26.1% of the total. Reporting peaked in 2022 at $18,496 and has fallen 82.7% since, to $3,200 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,264in general payments, 2019–2025

Across 47 payments — averaging $835.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$10K
  • Janssen Scientific Affairs, LLC$9K
  • Janssen Research & Development, LLC$6K
  • Photocure Inc$5K
  • Pfizer$4K
  • Janssen Global Services, LLC$2K
  • plus $2K from 3 others
$992,649in research payments, 2019–2025

Across 109 payments — averaging $9106.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$855K
  • Merck$96K
  • Ferring Pharmaceuticals AS$28K
  • Urogen Pharma, Inc.$14K

What the payments were for

  • Consulting fees$30,18077%
  • Speaking & faculty fees$3,1008%
  • Travel & lodging$4,48611%
  • Food & beverage$1,3984%
  • Education$990%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,264 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$112,428
Medicare patients
335
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron19$11,346
Tamsulosin Hcl249$2,596
Finasteride54$844
Oxybutynin Chloride ErOxybutynin Chloride18$619
Methenamine Hippurate13$543
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim51$237
Alfuzosin Hcl ErAlfuzosin Hcl16$206
Ciprofloxacin Hcl13$51
Cephalexin15$32
Tramadol Hcl20$19

Paid to pharmacies, not to this prescriber.

Other urology in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →